IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Advisory Services Network LLC

Advisory Services Network LLC trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 716 shares of the company’s stock after selling 268 shares during the period. Advisory Services Network LLC’s holdings in IDEXX Laboratories were worth $296,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $412,258,000. Flossbach Von Storch SE boosted its stake in IDEXX Laboratories by 5,439.3% during the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after purchasing an additional 464,791 shares during the last quarter. William Blair Investment Management LLC grew its holdings in shares of IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock worth $174,527,000 after buying an additional 369,471 shares in the last quarter. Assenagon Asset Management S.A. raised its position in shares of IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after buying an additional 316,048 shares during the last quarter. Finally, Seilern Investment Management Ltd purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth about $113,104,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $411.72 on Friday. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The stock’s fifty day moving average is $422.37 and its two-hundred day moving average is $431.22. The company has a market capitalization of $33.37 billion, a P/E ratio of 38.59, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on IDXX. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Stifel Nicolaus reduced their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research report on Monday, April 14th. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Finally, Piper Sandler raised their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.